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Background. Development of hydroxyethyl starches (HES) with a low impact on blood 
coagulation but a long intravascular persistence is of clinical interest. A previous in vitro study 
showed that low substituted high molecular weight HES does not compromise blood coagulation 
more than medium molecuiar weight HES. ln the present study we assessed the individual effects 
on blood coagulation of molar substitution and C2/C6 ratio of a high molecular weight HES. 
Methods. Blood was obtained from 30 healthy patients undergoing elective surgery and mixed 
with six high molecular weight (700 kDa) HES solutions differing in their molar substitution 
(0.42 and 0.51) and C2/C6 ratio (2.7, 7 and 14) to achieve 20, 40 and 60% dilution. Blood 
coagulation was assessed by Thrombelastograph® analysis (TEG) and plasma coagulation tests. 
Data were compared using a three-way analysis of variance model with repeated measures on the 
three factors. 
Results. Higher molar substitution compromised blood coagulation most (for all TEG 
parameters, P<0.05). The lowest C2/C6 ratio was associated with the lowest effect on blood 
coagulation; r (P<0.001 ), angle a (P=0.003) and coagulation index (P<0.001 ). No effect on k and 
maximum amplitude was observed (P for both >0.50). The higher molar substitution was 
associated with a lesser increase in PT (P=0.007) and a greater decrease in factor VIII 
(P=O.O 10). PTT, functional and antigenic von Willebrand factors were not significantly influenced 
by molar substitution (P for all >0.20). No significant differences between solutions with the same 
molar substitution but different C2/C6 ratios were found in plasma coagulation parameters 
(P for all >0.05). 
Conclusions. TEG analysis indicates that high molecular HES with a molar substitution of 0.42 
and a C2/C6 ratio of 2.7 has the lowest effect on in vitro human blood coagulation. 
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Hydroxyethyl starches (HES) are widely used plasma 
substitutes. 1-4 The clinical use of HES is limited by its 
impact on blood coagulation associated with a reduction 
of circulating levels of factor VIII and von Willebrand 
Factor (vWF) in a greater proportion than expected by 
plasma dilution.5- 7 Direct inhibition of platelet function 
through binding of HES to the platelet surface may also 
contribute to the blood coagulation compromising effects 
of HES.4 8 
HES is a modified branched natural polymer of amylo-
pectin. Besides its molecular weight, HES is characterized 
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Fig 1 Design of the trial: the blood was diluted at 20, 40 and 60% with each of the six blinded solutions (A, B, C, D, E and F) in polystyrene tubes 
yielding 5 ml of blood-HES mixtures. 
by its molar substitution, which expresses the average 
number of hydroxethyl groups per unit of glucose, and by 
the C2/C6 ratio, which describes more precisely the substi-
tution pattern: indeed, the hydroxyethyl units can be intro-
duced at positions 2, 3 and 6 of the glucose unit but most 
frequently at positions C2 and C6, so that the C2/C6 ratio is 
commonly indicated.2 4 
There was a generally held view that low molecular 
weight HES affects blood coagulation to a lesser extent 
than high molecular HES. Indeed, studies comparing high 
vs medium and low molecular weight HES confinned this 
advantage of medium and low molecular weight HES. 5 9 
However, in these studies, a reduction in molecular weight 
bas always been associated with a reduction in molar 
substitution. 
A preliminary in vitro study10 showed that two high 
molecular HES solutions with a molar substitution of 0.4, 
HES 500/0.4 and HES 800/0.4 (molecular weight/molar 
substitution), had a slightly reduced effect on blood coagu-
lation compared with HES 200/0.5. In addition, an in vivo 
study showed that, at low substitution, high molecular 
weight HES did not compromise blood coagulation to a 
greater extent than low molecular weight HES.11 We tested 
the hypothesis that molar substitution might be a key 
factor in determining the effect of a HES solution on 
blood coagulation. 
The present study assesses systematically the individual 
effects of molar substitution and C2/C6 ratio and the 
possibility of an interaction between these two parameters 
on the reduced coagulation produced by high molecular 
weight HES. 
Materials and methods 
This study of 30 patients was approved by our local ethics 
committee and each patient gave written informed consent. 
Patients between 18 and 80 yr of age undergoing varions 
surgical procedures were enrolled. Exclusion criteria were 
emergency surgery, a history of preoperative coagulation 
disorders, anticoagulation, treatment with acetylsalicylic 
acid or nonsteroidal anti-infiammatory drngs within 5 days 
before surgery, history of renal dysfunction or increased 
sernm creatinine levels (> 120 JLmol litre -l ), history of 
liver dysfunction or increased plasma levels of aspartate 
aminotransferase (>50 u litre -l) or alanine aminotransferase 
(> 50 u litre -l ), treatment with HES solutions within 30 days 
before surgery and ASA III or IV classification as judged 
by the responsible anaesthesiologist. A standard prophylaxis 
of 3000 u of s.c. low molecular weight heparin the day 
before surgery was allowed. 
Eighty millilitres of blood was removed from an antecu-
bital vein by direct venipuncture using a 19 gauge butterfiy 
connected to 10 ml monovettes containing 3.13% trisodium 
citrate (S-Monovette 10 ml 9 NC, Sarstedt, Nümbrecht, 
Germany). The first 10 ml of blood was discarded to 
avoid activation of blood coagulation. 
The blood from eight citrated monovettes was added into 
one polystyrene tube to produce one homogenous sample, 
and the whole blood was then incubated at 37°C for 1 h. 12 
The blood was then diluted. All 18 different possible 
dilutions (six different HES solutions at three dilutions; 
see Fig. 1) were initially made with one blood sample 
using blinded HES solutions labelled A, B, C, D, E and 
F. The diluted samples were again maintained for 1 h at 
37°C in an incubator.12 
TEG analysis was performed using two computerized 
Thrombelastograph® coagulation analysers 5000 (TEG, 
Haemoscope Corporation, Niles, IL, USA). Four samples 
were analysed at a time and the sequences of analysis and 
the TEG channels were randomly chosen for each patient 
using the randomly permuted blocks method. One millilitre 
of diluted blood was added to a tube containing 1 % kaolin. 
The tube was mixed and an aliquot of 340 fLl kaolin 
activated blood was then placed into the TEG cup contain-
ing 20 JLl of 2 M CaC12 . TEG analysis started immediately. 
Haemoglobin concentration was dete1mined with a blood 
gas analyser (Bayer Diagnostic Ltd, model 865, Bayer, 
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Zürich, Switzerland) using arterial blood samplers contain-
ing lyophilized lithium heparin (Marquest Quik A.B.G., 
Englewood, CO, USA). 
For prothrombin time (PT), activated partial throm-
boplastin time (aPIT), factor VIII and vWF measurements, 
samples were centrifuged at 3000 1pm for 15 min at 4°C 
(Rotanta/RP, Hettich, Bach, Switzerland). PT and aPTT 
were determined on an automated coagulation analyser 
(BCS, Dade Behring, Marburg, Germany) using a PT 
reagent containing recombinant tissue factor (Innovin®, 
Dade Behring) and an aPTT reagent containing ellagic 
acid (Actin FS®, Dade Behring), respectively. Factor VIII 
was assessed functionally using factor VIII-deficient plasma 
(Helena Haemostasis Systems Ltd, Sunderland, Tyne and 
Wear, UK). Functional activity of vWF was determined in a 
commercial ristocetin-cofactor assay (vWF RCA, Dade 
Behring) on an automated coagulation analyser (BCS, 
Dade Behring). Briefly, vWF activity was assessed by the 
ability to agglutinate fixed human platelets in the presence 
of ristocetin. Agglutination was turbidimetrically measured 
by the coagulation analyser. Antigenic vWF levels were 
assayed by a commercial ELISA kit (Asserachrom vWF 
antigenic, Roche Diagnostics, Rotkreuz, Switzerland) 
according to the manufacturer's instrnctions. 
HES syntheses 
Thin-boiling waxy maize starch was suspended in water, 
activated by means of sodium hydroxide, and allowed to 
react with ethylene oxide for 2 h at 40°C. The amounts of 
waxy maize starch and ethylene oxide were chosen to yield 
HES with molar substitutions of 0.42 and 0.51. HES C2/C6 
ratios of 2. 7, 7 and 14 were obtained by changing the quant-
ities of sodium hydroxide during hydroxyethylation. All raw 
HES species were hydrolysed by hydrochlmic acid to 
molecular weights of 700 kDa, treated with activated car-
bon, pmified by ultra-filtration and diluted to a final con-
centration of 6% (w/v) in isotonie saline, filled in glass 
bottles of 500 ml each, and heat-sterilized at 121°C for 
20 min. HES synthesis was pe1formed in the laboratories 
of B. Braun Medical SA, Crissier, Switzerland. 
HES characterization 
Mean molecular weight (Mw) of HES was determined by 
GPC-MALLS (Wyatt Technology, Woldert, Ge1many) at a 
flow rate of 1 ml min- 1 in a 70 mM phosphate buffer pH 7.0 
using serial GPC columns HEMA Bio 40, 100 and 1000 
(PSS, Mainz, Germany). Mw was calculated using ASTRA 
Software (Wyatt Technology, Woldert, Germany). 
Molar substitution was determined by gas chromato-
graphy after transforming hydroxyethyl groups into ethyl 
iodine by hyd1iodic acid in the presence of adipic acid 
using a gas chromatograph (Perkin Elmer Autosystem; 
Boston, MA, USA). C2/C6 ratio was determined after 
hydrolysis of HES by sulphuric acid and gas chromato-
graphie separation of the silylated hydroxyethylated glucose 
derivatives using a gas chromatograph (Carlo Erba Mega 
5300; Milan, ltaly). 
Statistical analysis 
Sample size bas been determined by a power analysis based 
on a previous in vitro study. 10 To obtain a power of 80% 
with an estimated difference between groups of 10% and a 
SD of 15% a total sample size of 30 patients has been determ-
ined with a type I error of 0.05. 
All data were calculated as changes vs baseline and repor-
ted as mean (sD). A three-way analysis of variance model 
with repeated measures on three ways was constrncted using 
the JMP 5.1 statistical package (SAS Institute, Inc., Cary, 
NC) for assessing the effect of molar substitution, C2/C6 
ratio and dilution, respectively, and all possible interaction 
between these factors. Thus, the vaiiability was partitioned 
into the following components: molar substitution, C2/C6 
ratio, interaction between molar substitution and C2/ 
C6 ratio, dilution, interaction between dilution and C2/C6 
ratio, interaction between dilution and molar substitution 
and interaction between all three factors. ' 
Results 
Plasma coagulation and TEG parameters were normal at 
baseline (Table 1). 
Dilution effect 
Haemoglobin decreased from 12.2 (1.3) to 9.8 (1.2) g d1- 1 
(20% dilution), 7.6 (1.0) g dl- 1 (40% dilution) and 
5.2 (0.8) g dl-1 (60% dilution) because of in vitro haemodi-
lution (P<0.001). No difference was found between the 
different HES solutions investigated. Dilution alone had a 
significant effect on all TEG parameters and on all plasma 
coagulation pai·ameters (P<0.001 for all pai·ameters): the 
more the blood was diluted, the more the coagulation 
was compromised (see Figs 2-5). 
Table 1 Baseline values. Data are mean (so). The following parameters were 
measured: TEG: r-time, k-time, angle ci., MA, shear elastic modulus (G) and CI; 
plasma coagulation: PT, aPTT, functional vWF and antigenic vWF (AG vWF) 
and factor VIII (F VIII) 
Normal range 
TEG parameters 
r-time (mm) 9.9 (1.1) 5-15 
k-time (mm) 3.1 (0.7) 2-6 
Angle ci. ( 0 ) 67.6 (4.2) 55-78 
MA (mm) 62.0 (7.4) 51-69 
G (Kd ç 1) 9.0 (2.4) 4.6-10.9 
CI 1.2 (1.4) -3 to 3 
Plasma coagulation 
PT (s) 10.1 (0.7) 7.7-11 
PTT (s) 32.4 (3.2) 26-36 
Functional vWF (%) 97.2 (39.9) 50-200 
AG vWF (%) 139.8 (57.9) 50-200 
F VIII(%) 89.5 (27.9) 50-200 
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Fig 2 Effects of molar substitution (MS) on TEG analysis. Blood samples were diluted with HES solutions with a MS 0.42 or 0.51 at dilutions of 
20% (Dil_20), 40% (Dil_ 40) and 60% (Dil_60). The following TEG parameters were measured: r-time (A), k-time (B), angle a (c), MA (D), shear 
elastic modulus (G) (E) and CI (F). Mean (so) changes vs baseline are depicted (11=30). 
Molar substitution effect 
TEG 
The higher molar substitution of 0.51 resulted in a greater 
compromise in blood coagulation for all TEG 
parameters: r-time (P<0.001) and k-time (P=0.031) were 
prolonged more when diluted using a HES solution with 
a molar substitution of 0.51 than when diluted using a 
HES solution with a molar substitution of 0.42 (Fig. 2A 
and B). Angle ex (P=0.008), maximal amplitude (MA) 
(P=0.013), G (P=0.003) and coagulation index (Cl) 
(P=0.007) showed a stronger decrease when diluted with 
a HES solution with a molar substitution of 0.51 than when 
diluted with a HES solution with a molar substitution of 0.42 
(Fig. 2c-F). 
Plasma coagulation 
PT (P=0.007) increase was lower and factor VIII (P=0.010) 
decrease was greater when diluted using a HES solution 
.with a molar substitution of 0.51 than when diluted using 
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Fig 3 Effects of molar substitution (MS) on plasma coagulation. Blood samples were diluted with HES solutions with a MS 0.42 or 0.51 al 
dilutions of 20% (Dil_20), 40% (Di!_ 40) and 60% (Dil_60). The following plasma coagulation parameters were measured: PT (A), factor VIII (B), 
aPTT (c), fünctional vWF (o) and antigenic vWF (E). Mean (so) changes vs baseline are depicted (11=30). 
a HES solution with a molar substitution of 0.42 (Fig. 3A 
and B) while aPTT (P=0.213), functional and antigenic 
vWFs (P=0.782 and 0.296, respectively) showed no signi-
ficant differences when diluted using HES solutions with 
a molar substitution of 0.51 or 0.42 (Fig. 3c-E). 
C2/C6 ratio ejjèct 
TEG 
HES solutions with different C2/C6 ratios affected r-time 
(P<0.001), angle a (P=0.003) and Cl (P<0.001) (Fig. 4A-c), 
while there were no significant differences between these 
solutions for k-time (P=0.513), MA (P=0.699) and G 
(P=0.246) (Fig. 4o-F). 
Plasma coagulation 
No significant differences between solutions with different 
C2/C6 ratios was found concerning PT (P=0.061), factor 
VIII (P=0.099), aPTT (P=0.086), functional and antigenic 
vWFs (P=0.916 and 0.064, respectively) (Fig. 5). 
Interactions 
A significant interaction between molar substitution and C2/ 
C6 ratio was found for r-time, angle a and CI (all P<0.001). 
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Fig 4 Effects of C2/C6 ratio on TEG analysis. Blood samples were diluted with HES solutions with C2/C6 ratio of 2.7, 7 or 14 at dilutions of 20% 
(Dil_20), 40% (Dil_40) and 60% (Dil_60). The following TEG parameters were measured: r-time (A), angle œ (B), CI (c), k-time (D), MA (E) and 
shear elastic modulus (G) (F). Mean (so) changes vs baseline are depicted (11=30). 
At a molar substitution of 0.42, k-time was progressively 
prolonged and angle a and CI were progressively reduced 
with increasing C2/C6 ratios (Fig. 6). In contrast, at a molar 
substitution of 0.51, a C2/C6 ratio of 7 resulted in a max-
imum compromise of blood coagulation (Fig. 6). No signi-
ficant interaction was found for k-time (P=0.786), MA 
(P=0.696), G (P=0.489), PT (P=0.343), factor VIII 
(P=0.874), aPTT (P=0.237), functional and antigenic 
vWFs (P=0.865 and 0.821, respectively). 
Discussion 
This study indicates that HES 700/0.42/2.7 (molecular 
weight/molar substitution/C2/C6 ratio) has a less 
pronounced effect on in vitro human blood coagulation 
than HES solutions of the same molecular weight with a 
higher degree of molar substitution and a higher C2/C6 
ratio. 
Molecular weight has been considered for a long time as a 
key factor in determining the compromising effects of HES 
on blood coagulation. 1 2 However, in recent years the devel-
opment of HES was always characterized by a concomitant 
reduction in molecular weight and molar substitution 
whereas the isolated effect of the molecular weight has 
not been systematically examined. Only recently Madjdpour 
and colleagues 11 tested HES molecules with different 
molecular weights but identical molar substitution. 
They found that, at a low molar substitution (0.42), high 
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Fig 5 Effects of C2/C6 ratio on plasma coagulation. Blood samples were diluted with HES solutions with C2/C6 ratio of 2.7, 7 or 14 at dilutions of 
20% (Di1_20), 40% (Di!_ 40) and 60 % (Dil_60). The following plasma coagulation parameters were measured: PT (A), factor VIII (B), aPTT (c), 
functional vWF (D) and antigenic vWF (E). Mean (so) changes vs baseline are depicted (11=30). 
molecular weight HES does not compromise blood coagu-
lation to a greater extent than low molecular weight HES 
with the same molar substitution. 
Treib and colleagues 13 studied the effect of molar sub-
stitution on blood coagulation. They showed that a HES 
200/0.62 solution affected coagulation of human blood 
more than HES 200/0.5. Unfortunately, the C2/C6 ratio 
of the solutions used was not indicated. Furthermore, 
only plasma coagulation but not TEG analyses have been 
pe1formed with the latter providing a complementary view 
on the process ofblood coagulation by testing the kinetics of 
the whole coagulation process. 14 
An in vitro study investigated the effect of HES 70/0.5/ 
3.2, HES 130/0.4/11.2 and HES 200/0.5/4.6 solutions on 
blood coagulation and found a reduced effect on blood 
coagulation of HES 130/0.4/11.2.15 The authors postulated 
that the smaller molar substitution might be responsible for 
this beneficial effect. However, in this study, molecular 
weight, molar substitution and C2/C6 ratio varied consid-
erably. Thus, it is difficult to allocate precisely an effect to 
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Fig 6 TEG parameters for which a significant interaction between molar substitution (MS) and C2/C6 ratio was found for HES solutions with a 
MS of 0.42 (left) or a MS of 0.51 (right) at dilutions of 20% (Dil_20), 40% (Di!_ 40) and 60% (Dil_60): r-time (A and B), angle œ (c and D) and CI 
(E and F). Mean (so) changes vs baseline are depicted (11=30). 
one parameter. Interestingly, Niemi and Kuitunen16 recently 
found in an in vitro study that HES 120/0.7 compromised 
blood coagulation less than RES 130/0.4. Unfortunately, the 
C2/C6 ratio was not described. 
This illustrates the need for systematic studies, which may 
only be possible in vitro, elucidating the complex interplay 
between molecular weight, molar substitution and the C2/ 
C6 ratio on the effect of RES on blood coagulation. In such a 
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study, we have now found that in high molecular HES a 
molar substitution of 0.42 and a C2/C6 ratio of 2.7 results in 
slightly reduced in vitro blood coagulation compromising 
effects. The observed differences are obviously small but the 
study design allowed paired comparisons and had thus the 
power to detect even minor differences. Extrapolating this 
finding to clinical practice is fraught with difficulties and 
certainly requires confirmatory in vivo studies. Also the 
effect of the relatively low C2/C6 ratio on pharmacokinetics 
needs to be equally assessed in vivo. 
Prophylactic s.c. low-molecular weight hepadn does not 
modify TEG parameters. 17 This is in keeping with the find-
ing that baseline TEG parameters were in the normal range 
in this study (Table 1), as they were in several previous 
studies.12 18 19 
The ideal properties of a HES solution may differ between 
the intraoperative and the postoperative pedod. Intraoper-
atively, a minimal effect on blood coagulation is certainly 
important. A longer intravascular retention time may be 
desirable after operation, whereas a certain blood coagula-
tion compromising effect may not necessarily be deleteri-
ous. In fact, McCrath and colleagues20 have recently shown 
that patients already with a minimal hypercoagulability at 
the end of surgery had a higher incidence of major throm-
boembolic complications such as ischaemic strokes, 
myocardial infarctions, deep venous thrombosis and venous 
thromboembolism after operation despite standard throm-
boembolic prophylaxis. 
In conclusion, a molar substitution of 0.42 and a C2/C6 
ratio of 2.7 were found to be associated with the least com-
promise on blood coagulation in high molecular (700 kDa) 
HES. Further studies are necessary to assess whether such 
a HES also compromises in vivo blood coagulation 
minimally and whether its intravascular retention is indeed 
higher than a low molecular, low substituted HES such as a 
HES 130/0.42. 
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